NetworkNewsWire
Editorial Coverage: The rapidly growing cannabis
industry has spawned a range of diverse companies focusing on
innovative technologies for cannabis cultivation, as well as the
development of cannabis-based medical therapies for an array of
diseases and ailments. The market has given rise to biotech
companies with exciting advances in product formulation and
delivery. At the cutting-edge of innovation, PreveCeutical
Medical Inc. (OTCQB: PRVCF) (CSE: PREV) (FSE: 18H) (PRVCF
Profile) has developed an innovative cannabidiol
(CBD)-based nose-to-brain delivery system for the relief of a
number of medical conditions. Another company, Lexaria
Bioscience Corp. (OTC: LXRP) (LXRP
Profile) has developed its own proprietary system for
CBD-based therapy delivery. And with a market cap of over $3.6
billion, GW Pharmaceuticals plc (NASDAQ: GWPH) is
an established giant in the cannabis biotech space developing
plant-derived cannabinoid therapeutics. Canadian cultivator
Canopy Growth Corp. (TSE: WEED) is an example of
yet another company that could benefit from its therapeutic
advances as the anticipated commercial availablity of
pharmaceutical-grade cannabis products is met by greater
demand.
The cannabis market is likely to surpass $31 billion by 2021,
billowing from its value of $6.5 billion in 2016, according to a
Brightfield Group report quoted by Forbes (http://nnw.fm/b75xW). A different report by investment
bank Cowen & Co. estimates that the market will increase to $50
billion by 2026 (http://nnw.fm/wmv6C). This caliber of growth, to a
large extent, is fueled by the increasing legalization of cannabis
for medical and recreational use in Canada and in many states
across the United States. As demand for cannabis-based medications
grows, the market will become increasingly competitive, compelling
companies to develop innovative therapies and delivery systems to
gain more traction in the marketplace.
Diverse Portfolio Creates Multiple Market
Opportunities
Headquartered in Vancouver, Canada, PreveCeutical
Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE:18H) started out
in 2009 as a partnership between established businessman and
venture capitalist Stephen Van Deventer, and entrepreneur Kimberley
Van Deventer. The synergy of the pair’s respective aptitudes led to
the creation of Cornerstone Global Partners, a venture capital and
business development company.
Today, PreveCeutical is a life science company that researches
and develops innovative solutions for preventative and curative
therapies through a combination of organic and Nature Identical™
products. With the preventative healthcare technologies market
expected to reach $432 billion by 2024 (http://nnw.fm/UF8u8), the company has made a strategic
decision to focus on warding off illness in the medically acute
areas of diabetes, obesity, pain management, neurological disorders
and cancer.
By maintaining a diverse portfolio of novel compounds and
products, PreveCeutical is able to compete in several niches of the
health care industry, including immunity-boosting sciences and
medicinal cannabis.
PreveCeutical has a product, CELLB9®, an oral dilute solution
utilizing select peptides from the blue scorpion, found only in the
Caribbean region. PreveCeutical’s “Nature Identical” research team
is building on proprietary chemistry to produce controlled venom
peptides that it hopes will be able to halt the progression of
cancers, while also exploring the peptides’ potential in responding
to other medical concerns related to pain management, metabolic
disorders, cancers, cardiovascular conditions and infectious
diseases.
PreveCeutical is currently in a joint venture with Sports 1
Marketing to focus on the therapeutic potential of the Natural
Identical venom’s peptides and proteins to treat mild brain injury
concussions in athletes.
The company is also currently working with four leading
Australian research centers to develop a curative therapy for
diabetes and obesity. This is a novel four-year program selectively
targeting the gene that encodes for the protein PTP-1B, implicated
and over-expressed in both Type-2 diabetes and obesity.
Globally, over $800 billion is spent on diabetes, with one
person dying every six seconds from the disease (http://nnw.fm/2OqnS) in 2014, presenting to
PreveCeutical significant market opportunity and the potential to
alter the diabetes landscape.
Notably, PreveCeutical’s innovative gene-silencing technology
would effectively disable the genetic signal that leads to
over-production of PTP-1B. This would bring this protein down to
safe, normalized levels that would prevent the body from storing
excessive fat.
PreveCeutical’s Groundbreaking Sol-Gel Delivery
System
PreveCeutical in November announced its approval from the
Environmental Hazards Unit of the Queensland Government (the
Australian state-level authority) to acquire, store and use
high-quality dried cannabis plant extracts, paving the way for the
company to advance its R&D program for the commercialization of
a new system for administering the drug (http://nnw.fm/47wwI).
The company believes its Sol-gel platform will be the first
FDA-approved, CBD-based nose-to-brain delivery system of its kind
to provide relief for pain, inflammation, seizures and neurological
disorders. PreveCeutical’s proprietary nasal formulations will be
designed for use by both adults and children. The company expects
to have this delivery platform fully tested, approved and primed
for deployment to licensed medical cannabis companies in 2019.
PreveCeutical’s Sol-gels are taken via nasal administration.
They gel rapidly on contact with mucosal tissue, paving the way for
direct nose-to-brain delivery. By circumventing first-pass
metabolism in the stomach, intestines and liver, bioavailability
may be dramatically improved, even compared to other nasal sprays
and alternative delivery systems. The gel stays in the nasal
passages, providing controlled CBD release while maintaining
activity for up to seven days. Its ease of application,
long-lasting effects and absence of negative side-effects may make
it attractive for patients over other delivery systems.
The Company’s Development and Management
Team
PreveCeutical Medical’s research team is led by Dr. Harendra
Parekh, Ph.D., based at the Pharmacy Australia Centre of Excellence
(PACE) at the University of Queensland. He is joined by Chief
Science Officer Dr. Makarand Jawadekar, Ph.D., who has 28 years of
experience in R&D with Pfizer Inc. They are supported by
research collaborators, Dr. Rakesh Veedu and Professor Grant Ramm.
Dr. Veedu is an emerging international expert in molecular
medicine, while Professor Ramm is currently head of a leading
medical research institute in Brisbane, Australia.
PreveCeutical also partners with industry experts and companies
in its drive to establish a leadership position in the preventative
health sciences sector. Its research and development partnership
with the University of Queensland’s commercialization company,
UniQuest, grants PreveCeutical rights to all intellectual property
arising from projects created by the partnership.
The Company’s management team has extensive experience in
research, product development, deep corporate strategy development
and leadership in capital markets. PreveCeutical is re-capitalizing
to fund its ambitious research and development program. Following a
private placement completed in July 2017, the company expects the
next round of financing to close in mid-February.
A recent Crystal Equity Research report summarizes the company’s
differentiated endeavors in health care, highlighting
PreveCeutical’s ability to raise the capital needed to execute its
business plans.
“Our bullish view on PreveCeutical Medical is influenced by the
Company’s plans to bring novel therapeutic compounds to the market
at a time when the preventative health care market is entering a
period of rapid growth. Management has demonstrated the ability to
garner investor support and raise capital at a critical time in its
development agenda, a recognized key to success for any health
sciences company. Management has also been successful in securing
research and development talent through a strategic relationship
with a respected and successful academic institution,” reads the
report (http://nnw.fm/Ho4v2).
Industry Comparables
Another innovative biotech, Lexaria
Bioscience Corp. (OTC: LXRP), has developed disruptive
delivery technology that facilitates healthier ingestion methods,
lower overall dosing and higher effectiveness of lipophilic active
molecules. The company out-licenses its delivery platform, which
has multiple patents pending in more than 40 countries. Patents
have been granted in the United States and Australia for the use of
its DehydraTECH™ delivery technology. This provides increased
intestinal absorption rates, faster delivery to the bloodstream and
taste-masking benefits for orally administered cannabinoids,
vitamins, non-steroidal anti-inflammatory drugs (NSAIDs), nicotine
and other molecules.
London-headquartered GW Pharmaceuticals plc (NASDAQ:
GWPH) focuses on discovering, developing and
commercializing new therapeutics across a wide range of disease
areas using its proprietary cannabinoid product platform. The
company commercialized the world’s first plant-derived cannabinoid
prescription drug, Sativex®, for the treatment of spasticity due to
multiple sclerosis. Together with its U.S. subsidiary, Greenwich
Biosciences, GW is proceeding with an orphan drug program for
childhood epilepsy. It has filed a New Drug Application (NDA) with
the FDA for its CBD-based drug Epidiolex for the adjunctive
treatment of Lennox-Gastaut Syndrome (LGS) and Dravet Syndrome.
Other products in its development pipeline include compounds in
Phase 1 and 2 trials for glioblastoma, schizophrenia and
epilepsy.
Canopy Growth Corp. (TSE: WEED) offers distinct
brands and curated cannabis varieties in dried, oil and capsule
form. The company operates seven cannabis production sites with
more than 665,000 square feet of production capacity, which
includes over 500,000 square feet of GMP-certified production area.
It has global reach, with operations in seven countries across four
continents. Canopy Growth educates healthcare practitioners and the
public on cannabis. Through its partly owned subsidiary Canopy
Rivers Corporation, the company builds its portfolio of stable
investments by incubating new entrants to the cannabis market.
Canopy Health Innovations, another partly owned subsidiary, focuses
on research for commercial opportunities and IP development.
These companies are rising to the challenges presented by the
increasing consumer demand for cannabis-based products. They are
positioning themselves to assume leadership positions in their
respective sectors of the cannabis industry to realize maximum
value for their shareholders.
For more information on PreveCeutical Medical Inc., please
visit: PreveCeutical
Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE:18H).
About NetworkNewsWire
NetworkNewsWire (NNW) is an information service that provides
(1) access to our news aggregation and syndication servers, (2)
NetworkNewsBreaks that summarize corporate news and
information, (3) enhanced press release services, (4) social media
distribution and optimization services, and (5) a full array of
corporate communication solutions. As a multifaceted financial news
and content distribution company with an extensive team of
contributing journalists and writers, NNW is uniquely positioned to
best serve private and public companies that desire to reach a wide
audience of investors, consumers, journalists and the general
public. NNW has an ever-growing distribution network of more than
5,000 key syndication outlets across the country. By cutting
through the overload of information in today’s market, NNW brings
its clients unparalleled visibility, recognition and brand
awareness. NNW is where news, content and information converge.
NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com
Please see full terms of use and disclaimers on the
NetworkNewsWire website applicable to all content provided by NNW,
wherever published or re-published: http://NNW.fm/Disclaimer
DISCLAIMER: NetworkNewsWire (NNW) is the source of the Article
and content set forth above. References to any issuer other than
the profiled issuer are intended solely to identify industry
participants and do not constitute an endorsement of any issuer and
do not constitute a comparison to the profiled issuer. The
commentary, views and opinions expressed in this release by NNW are
solely those of NNW. Readers of this Article and content agree that
they cannot and will not seek to hold liable NNW for any investment
decisions by their readers or subscribers. NNW are a news
dissemination and financial marketing solutions provider and are
NOT registered broker-dealers/analysts/investment advisers, hold no
investment licenses and may NOT sell, offer to sell or offer to buy
any security.
The Article and content related to the profiled company
represent the personal and subjective views of the Author, and are
subject to change at any time without notice. The information
provided in the Article and the content has been obtained from
sources which the Author believes to be reliable. However, the
Author has not independently verified or otherwise investigated all
such information. None of the Author, NNW, or any of their
respective affiliates, guarantee the accuracy or completeness of
any such information. This Article and content are not, and should
not be regarded as investment advice or as a recommendation
regarding any particular security or course of action; readers are
strongly urged to speak with their own investment advisor and
review all of the profiled issuer’s filings made with the
Securities and Exchange Commission before making any investment
decisions and should understand the risks associated with an
investment in the profiled issuer’s securities, including, but not
limited to, the complete loss of your investment.
NNW HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.
This release contains “forward-looking statements” within the
meaning of Section 27A of the Securities Act of 1933, as amended,
and Section 21E the Securities Exchange Act of 1934, as amended and
such forward-looking statements are made pursuant to the safe
harbor provisions of the Private Securities Litigation Reform Act
of 1995. “Forward-looking statements” describe future expectations,
plans, results, or strategies and are generally preceded by words
such as “may”, “future”, “plan” or “planned”, “will” or “should”,
“expected,” “anticipates”, “draft”, “eventually” or “projected”.
You are cautioned that such statements are subject to a multitude
of risks and uncertainties that could cause future circumstances,
events, or results to differ materially from those projected in the
forward-looking statements, including the risks that actual results
may differ materially from those projected in the forward-looking
statements as a result of various factors, and other risks
identified in a company’s annual report on Form 10-K or 10-KSB and
other filings made by such company with the Securities and Exchange
Commission. You should consider these factors in evaluating the
forward-looking statements included herein, and not place undue
reliance on such statements. The forward-looking statements in this
release are made as of the date hereof and NNW undertake no
obligation to update such statements.
Source:
NetworkNewsWire
Contact:
NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com
GW Pharmaceuticals (NASDAQ:GWPH)
Historical Stock Chart
From Mar 2024 to Apr 2024
GW Pharmaceuticals (NASDAQ:GWPH)
Historical Stock Chart
From Apr 2023 to Apr 2024
